United States · Markets & Finance · Yahoo Finance

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Published by Yahoo Finance · United States 10 h ago

Johnson & Johnson (NYSE: JNJ) reported new Phase 3 results for oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress. The oral IL-23 inhibitor showed sustained skin…

Read the full article on Yahoo Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

TechCrunch

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

Fortune

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Share

Also worth reading

Federal judge calls Flock ‘indiscriminate mass surveillance’

Key deals this week: Onsemi, Mattel, Nebius, Advanced Micro Devices, and more

OpenAI leader who quit says he can do more for safety from outside the company

Iran Is Losing Some of Its Leverage Over the Strait of Hormuz

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

U.S. debt is increasingly at the mercy of the market as interest costs surge while elections add more risk to the debt ceiling, ratings agency warns